IL-17和IL-35在甲状腺癌患者血清中的水平及临床意义

Serum IL-17,IL-35 levels and clinical significance in patients with thyroid cancer

目的探讨白细胞介素17(IL-17)、白细胞介素35(IL-35)在甲状腺癌患者血清中的水平及临床意义。方法选择2010年1月至2013年12月期间84例甲状腺肿瘤患者为研究对象。84例甲状腺肿瘤中甲状腺癌52例,甲状腺腺瘤32例。52例甲状腺癌中,甲状腺乳头状癌22例,甲状腺滤泡状癌18例,甲状腺未分化癌12例。甲状腺癌病理分期:II期,20例;III期,18例;IV期,14例。另选择同期体检的健康者56例为对照。检测受试者血清IL-17、IL-35水平,并对血清IL-17、IL-35水平与年龄、病程、甲状腺癌恶性程度、病理分期、BMI进行相关性分析。结果甲状腺癌组血清IL-17水平高于甲状腺腺瘤组和对照组,差异有显著性(P<0.01);甲状腺癌组血清IL-35水平低于甲状腺腺瘤组和对照组,差异有显著性(P<0.01);甲状腺腺瘤组和对照组血清IL-17、IL-35水平无显著差异(P>0.05);随着甲状腺癌分化程度的降低,血清IL-17水平呈上升趋势,且三组间两两比较差异均有显著性(P<0.01);随着甲状腺癌分化程度的降低,血清IL-35水平呈下降趋势,且三组间两两比较均有统计学差异(P<0.01);随着甲状腺癌病理分期的增加,血清IL-17水平呈上升趋势,且三组间两两比较差异均有显著性(P<0.01);随着甲状腺癌病理分期的增加,血清IL-35水平呈下降趋势,且三组间两两比较差异均有显著性(P<0.01);血清IL-17水平与甲状腺癌恶性程度、病理分期均呈正相关(P<0.05),血清IL-35水平与甲状腺癌恶性程度、病理分期均呈负相关(P<0.05);血清IL-17水平与血清IL-35水平呈负相关(r=-0.328,P=0.022)。结论 IL-17在甲状腺癌患者血清中呈现高表达,而IL-35在甲状腺癌患者血清中呈现下降趋势,IL-17、IL-35与甲状腺癌发病、分化程度及进展密切相关。

Objective To study serum IL - 17,IL - 35 levels and clinical significance in patients with thyroid cancer. Methods From January 2010 to December 2010,84 cases of thyroid cancer patients were selected as the research object. 52 thyroid carcinoma in 84 cases of thy-roid tumors,32 cases of thyroid adenoma. 22 cases of thyroid papillary carcinoma in 52 cases of thyroid cancer,18 cases of thyroid follicular carci-noma,12 cases undifferentiated thyroid carcinoma. Thyroid cancer pathological stages：Stage II,20 cases;Stage III,18 cases. Stage IV,14 ca-ses. During the same period in our hospital 56 cases of healthy subjects were selected as control. Statistical level of serum IL - 17,IL - 35 sub-jects,and the level of serum IL - 17,IL - 35 and age,course of the disease,malignant degree of thyroid carcinoma,pathologic stage,BMI were analyzed by correlation analysis. Results The IL - 17 level in thyroid cancer group serum was higher than that of thyroid adenoma group and the control group,and there are statistical differences（ P ﹤ 0. 01）. The level of serum IL - 35 of thyroid cancer group is less than that of thyroid ad-enoma group and the control group,with statistical difference（ P ﹤ 0. 01）. The serum IL - 17,IL - 35 level of thyroid adenoma group and the control group were similar,without obvious difference（ P ﹥ 0. 05）. With the decrease of differentiated thyroid cancer,serum level of IL - 17 is increasing,and the comparison between two groups have statistical difference（ P ﹤ 0. 01）. With the reduction of differentiated thyroid cancer, the serum levels of IL - 35 decrease. The two comparison between the three groups were statistically significant（ P ﹤ 0. 01）. With the increase of thyroid cancer pathological staging,the serum level of IL - 17 is on the rise,and the comparison between two groups were statistically significant （ P ﹤ 0. 01）. With the increase of thyroid cancer pathological staging,the serum level of IL - 35 showed a downward trend,and the comparison between two groups have statistical difference（ P ﹤ 0. 01）. Serum level of IL - 17 and malignant degree of thyroid carcinoma was a positive corre-lation,pathological staging（ P ﹤ 0. 05）. The serum level of IL - 35 with the malignant degree of thyroid carcinoma,and negatively correlated with pathological stage（ P ﹤ 0. 05）. Serum level of IL - 17 negatively correlated to the level of serum IL - 35（ r = 0. 328,P = 0. 328）. Con-clusion IL - 17 show high expression in thyroid cancer patients serum,and IL - 35 patients with thyroid carcinoma showed a trend of decline in serum,IL - 17,IL - 35 are closely related to thyroid cancer incidence,degree of differentiation and development.